Sorrento Files IND for STI-1499 (COVI-GUARD) in Patients Hospitalized with COVID-19
Shots:
- Sorrento has filed an IND for STI-1499 in patients hospitalized with COVID-19. In preclinical studies- STI-1499 has demonstrated 100% neutralizing effect (in vitro) against the highly contagious D614G mutant strain at a low dose
- Additionally- animal model data confirms the neutralizing profile and high potency of Ab- expected effective dose in human to be at least 5 times lower than current known Abs being assessed in other active trials
- Sorrento has initiated cGMP manufacturing to produce 50-000 doses- expected to be available by the end of 2020- in anticipation of a potential EUA
Ref: Sorrento | Image: Blogger
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]
